Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0001367644-25-000052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-10 | 2025-03-06 | EBS | Williams Paul Anthony | SVP, Products Business | A - Grant | $0.00 | +62.5K | 86.3K | +262% | $0 |
| D | 2025-03-10 | 2025-03-06 | EBS | Williams Paul Anthony | SVP, Products Business | A - Grant | $0.00 | +62.5K | 210.1K | +42% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-06 | A | A | 62,500 | $0.00 | 86,335 | D | — | — | (F1) Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
| 2 | Derivative | Employee Stock Options (Right to Buy) | 2025-03-06 | A | A | 62,500 | $0.00 | 210,114 | D | $5.80 · — to 2032-03-05 | 62,500 Common Stock | (F2) Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |